Skip to main content

Table 1 Details of annual mass drug administration (MDA) delivery in LF endemic sub-Saharan African countries

From: Continental-scale, data-driven predictive assessment of eliminating the vector-borne disease, lymphatic filariasis, in sub-Saharan Africa by 2020

Countrya

Vector genusb

MDA type

IUs (initial phase: 1–3 years)

Start year

% program drug coverage (range)

IUs (expansion phase: 4–5 years)

Start year

% program drug coverage (range)

IUs (later phase)

Start year

% program drug coverage (range)

Benin

Anopheles

IVM-ALB

9

2002

79.35 (77.8–80.5)

21

2004

81.23 (75.4–85.6)

25

2013

100

Burkina Faso

Anopheles

IVM-ALB

22

2001

74.43 (68.4–77.8)

59

2005

80.3 (77.2–81.8)

57

2013

71.4

Cameroon

Anopheles

IVM-ALB

12

2008

75.95 (74.6–77.3)

84

2010

73.9 (69.8–78.0)

123

2012

80.35 (79.9–80.8)

Comoros

Culex

DEC-ALB

2

2001

73.2 (56.9–85.7)

–

–

–

–

–

–

Congo

Anopheles

IVM-ALB

–

–

–

–

–

–

5

2013

92.8

Cote d’Ivoire

Anopheles

IVM-ALB

3

2009

78.9

13

2010

31.5

5

2013

70

Egypt

Culex

DEC-ALB

28

2000

93.92 (91.0–96.7)

–

–

–

–

–

–

Ethiopia

Anopheles

IVM-ALB

5

2009

77.53 (72.7–81.7)

–

–

–

27

2012

76.4 (74.2–78.6)

Ghana

Anopheles

IVM-ALB

22

2000

62.28 (23.9–74.1)

66

2005

72.15 (63.9–75.2)

91

2013

76.8

Guinea Bissau

Anopheles

IVM-ALB

–

–

–

–

–

–

33

2011

71.7 (69.4–74.0)

Kenya

Anopheles and Culex

DEC-ALB

1

2002

81.20

3

2003

71.5 (62.7–79.5)

9

2011

58.3

Liberia

Anopheles

IVM-ALB

–

–

–

–

–

–

13

2012

90.7 (81.1–100)

Madagascar

Anopheles

DEC-ALB

3

2005

81.40

25

2006

76.68 (74.6–79.5)

39

2010

66.53 (66.3–66.9)

Malawi

Anopheles and Culex

IVM-ALB

9

2008

80.50

–

–

–

26

2009

81.68 (79.8–83.0)

Mali

Anopheles

IVM-ALB

9

2005

80.70 (78.2–83.2)

46

2007

78.75 (61.6–85.1)

45

2013

82.10

Mozambique

Culex

IVM-ALB

18

2009

71.81

51

2010

77.85 (74.4–81.3)

94

2013

85

Niger

Anopheles

IVM-ALB

9

2007

72.20

20

2008

65.60 (58.7–72.5)

30

2010

69.28 (63.7–72.7)

Nigeria

Anopheles

IVM-ALB

14

2000

41.53 (32.3–53.7)

31

2003

72.63 (64.2–77.1)

135

2009

58.08 (48.9–73.6)

Senegal

Anopheles

IVM-ALB

7

2007

73.60 (66.8–78.7)

–

–

–

13

2013

49.3

Sierra Leone

Anopheles

IVM-ALB

6

2007

61.30

13

2008

72.1 (70.1–74.1)

14

2010

79.5 (77.7–80.6)

Sudan

Culex

IVM-ALB

–

–

–

–

–

–

2

2013

87.8

Tanzania

Anopheles and Culex

IVM-ALB

17

2000

76.10 (59.1–100.0)

25

2003

70.54 (60.5–79.9)

84

2011

73.03 (65.8–77.1)

Togo

Anopheles

IVM-ALB

7

2000

67.20

–

–

–

–

–

–

Uganda

Anopheles

IVM-ALB

6

2002

66.80 (53.5–76.0)

38

2007

67.5 (62.4–72.4)

41

2012

66.9 (66.8–67.0)

  1. MDA was implemented across a country in a staggered manner, effectively creating several cohorts of implementation units (IUs), namely those that began to receive MDA in the initial phase, the expansion phase, or the later phase
  2. aThe following countries not listed in the table had not yet started MDA as of 2015: Angola, Central African Republic, Chad, Democratic Republic of Congo, Djibouti, Equatorial Guinea, Gabon, Guinea, South Sudan, The Gambia, Zambia, and Zimbabwe
  3. bVector genus information was retrieved from WHO [49]
  4. IVM ivermectin, ALB albendazole, DEC diethylcarbamazine citrate
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us